Market Access with CIPM: Your Guide to Spain’s Pharmaceutical Pricing Authority

The Interministerial Commission on Medicine Prices (Comisión Interministerial de Precios de los Medicamentos, CIPM) is a collegiate body within Spain’s Ministry of Health. It is responsible for setting the maximum industrial price for each pharmaceutical product included, or to be included, in the National Health System’s (SNS) pharmaceutical provision. ​sanidad.gob.es

Core Functions of the CIPM

The CIPM’s primary responsibilities include:

• Setting Maximum Industrial Prices: Establishing the maximum industrial price for each pharmaceutical product financed by public funds, ensuring that medicines are accessible to the public at non-abusive economic conditions. ​lamoncloa.gob.es
• Decision-Making on Public Financing: Determining whether new medicines will receive public financing based on reports prepared by the Subdirectorate General for Quality of Medicines and Health Products. ​farmaindustria.es
• Price Adjustments in Exceptional Health Situations: Setting maximum retail prices for medicines and products during exceptional health situations to protect public health. ​lamoncloa.gob.es

Composition of the CIPM

The CIPM is composed of representatives from the Dirección General de Cartera Común de Servicios del Sistema Nacional de Salud y Farmacia (DGCF), and various ministries and autonomous communities, ensuring a comprehensive approach to pharmaceutical pricing. 

Chair: Mr Javier Padilla Bernáldez, Secretary of State for Health

Contact Details for the CIPM

Website: https://www.sanidad.gob.es/en/areas/farmacia/precios/comisionInteministerial/home.htm

Contact Details:

• Address: Paseo del Prado 18-20, 28071 Madrid, Spain
• Phone: +34 915964015
• Email: cartera-farmacia@sanidad.gob.es

Challenges and Opportunities in Working with the CIPM

Engaging with the CIPM involves:

• Understanding Pricing Criteria: Familiarity with the objective criteria used by the CIPM to set medicine prices is crucial for successful market access.​
• Timely and Accurate Submissions: Ensuring that all necessary documentation is complete and submitted promptly to facilitate the evaluation process.​
• Demonstrating Value and Efficacy: Providing robust evidence that new treatments offer tangible benefits and proven efficacy within the SNS framework.​

Effective pricing and reimbursement (P&R) submissions can lead to a positive reimbursement recommendation by the DGCF and a positive P&R decisionsby the CIPM, leading to optimized market entry and favorable pricing and reimbursement outcomes in Spain.​

Opportunities with Justin Stindt Consultants

Justin Stindt’s expertise ensures:​

• Expert Consultant CIPM Submissions: Creating high-quality submissions for medicine pricing evaluations.​
• Market Access CIPM Strategies: Developing strategies aligned with the CIPM’s evaluation framework to optimize market access.​
• Specialist CIPM Processes: Providing insights into the CIPM’s procedures to enhance compliance and expedite approvals.​

Justin Stindt Consultants specializes in assisting clients to effectively engage with the Spanish P&R authorities and CIPM members to achieve successful market access in Spain.​